Astria Therapeutics, Inc. (ATXS)

10,29 +0,72 (+7,52%) Ab 01:20PM EDT. Markt geöffnet.

Astria Therapeutics, Inc.

75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971
https://www.astriatx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 59

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Jill C. Milne Ph.D.	Co-Founder, CEO, President & Director	938,78k	N/A	1968
Mr. Noah C. Clauser CPA	CFO & Treasurer	621,41k	N/A	1974
Dr. Christopher J. Morabito M.D.	Chief Medical Officer	661,57k	N/A	1971
Mr. Benjamin S. Harshbarger J.D.	Chief Legal Officer	621,91k	N/A	1969
Ms. Keri McGrail	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Andrea L. Matthews	Chief Business Officer	N/A	N/A	1982
Mr. Andrew A. Komjathy	Chief Commercial Officer	N/A	N/A	1964
Mr. John Ruesch	Senior Vice President of Pharmaceutical Sciences & Technical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Corporate Governance

Astria Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 7, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.